IFNG and neoplasm: Intriguingly, ALT-803 was found to substantially enhance in vitro NK cell degranulation, IFN-γ production, and rituximab-mediated ADCC against B cell lymphoma cell lines and primary follicular lymphoma cells, and combination treatment with ALT-803 and rituximab in two B cell lymphoma models in vivo resulted in significantly reduced tumor cell burden and improved survival (43).